The American Heart Association (AHA) has issued a statement to provide guidance on the use of cardiac imaging in cancer patients undergoing therapy, which it published recently in Circulation.
The AHA’s statement addresses the use of echocardiography and cardiovascular MRI, CT, SPECT, and PET imaging and aims to provide consensus on their appropriate use in clinical cardio-oncology, the association said in its release.
Echocardiography should be the first-line imaging modality used for assessing cardiac function in patients receiving treatment that can lead to cancer therapy-related cardiac dysfunction, according to the AHA.
The full article is available here.
